Here's what experiments TRISH is launching aboard Axiom Space's next mission. Photo via NASA

Houston's Translational Research Institute for Space Health, or TRISH, will launch six more experiments into space this spring aboard Axiom Space's Ax-2 mission, the organization announced this week.

The biomedical research conducted through TRISH, in consortium with CalTeach and MIT, will look into how space travel impacts everything from motion sickness to memory over the course of the mission's 10-day stint on the International Space Station.

The crew will consist of four astronauts: Commander Peggy Whitson (previously with NASA), Pilot John Shoffner and Mission Specialists Ali AlQarni and Rayyanah Barnawi. It's a historic team, bringing the first female private space crew commander and the first Saudi astronauts to the ISS.

“Insights gathered from this work improve our understanding of how the human body and mind respond to spaceflight, helping us to prepare future astronauts to remain safe and healthy during longer-duration missions," Dr. Dorit Donoviel, TRISH executive director and professor in the Center for Space Medicine at Baylor College of Medicine, says in a statement.

The six projects onboard the mission have been developed by researchers within TRISH as well as the University of Pennsylvania Perelman School of Medicine, Johns Hopkins University and Baylor College of Medicine. They aim to assess the following:

  • Spaceflight participants’ performance in memory, abstraction, spatial orientation, emotion recognition, risk decision making and sustained attention before and after the mission -Astronauts’ inner ears and eyes' response to motion before and after space travel and how this relates to motion sickness and nausea during launch and landing
  • The effects of spaceflight on the human body at the genomic level
  • Changes to the eyes and brain during spaceflight
  • Astronaut's sleep, personality, health history, team dynamics and immune-related symptoms
  • Sensorimotor abilities and changes in space and how this can impact astronauts' ability to stand, balance and have full body control on the moon

Some of this information will become part of TRISH’s Enhancing eXploration Platforms and ANalog Definition, or EXPAND, program, which aims to boost human health on commercial space flights through its database. The program launched in 2021.

Ax-2 is Axiom's second all-private astronaut mission to the ISS and will launch out of NASA’s Kennedy Space Center in Florida aboard a SpaceX's Dragon spacecraft. Axiom was first established in 2016 with the goal of building the world's first commercial space station.

TRISH is also slated to launch nine experiments on board SpaceX's Polaris Dawn mission, which is now expected to launch this summer. The research aboard Polaris Dawn is intended to complement research supported by TRISH on the Inspiration4 all-civilian mission to orbit, which was also operated by SpaceX in 2021.

Axiom Space has announced plans for its third commercial space launch and revealed details of its high-tech spacesuit. Photo courtesy of NASA

Houston space tech company secures third NASA mission, reveals new spacesuits

ready for liftoff

A Houston-based space tech company has revealed details on two of its commercial partnerships with NASA.

NASA and Axiom Space have again signed a mission order for a private astronaut mission to the International Space Station. The mission will commence sometime in November or on and will be from the agency’s NASA’s Kennedy Space Center in Florida. Axiom Mission 3 is the third mission of its kind and, according to a statement from NASA, is expected to be a 14-day trip.

The ISS's Multilateral Crew Operations Panel will approve four proposed crew members and two back up crew submitted by Axiom for the Ax-3 mission. The crew will be expected to train for their flight with NASA, international partners, and SpaceX beginning this spring, according to NASA.

“Axiom Space’s selection to lead the next private astronaut mission to the International Space Station enables us to continue expanding access to nations, academia, commercial entities, and emerging industries to research, test, and demonstrate new technologies in microgravity,” says Michael Suffredini, CEO and president of Axiom Space, in the release. “As NASA’s focus shifts back to the Moon and on to Mars, we are committed to transforming low-Earth orbit into a global space marketplace, where access to space moves beyond the partners of the space station to nations, institutions and individuals with new ideas fueling a thriving human economy beyond Earth.”

Axiom's historic first commercial launch was in spring of 2022, and Ax-2, which will launch the first Saudi astronauts to visit the ISS, is expected to launch this spring. In addition to these two missions, Axiom has been tasked by NASA to develop spacesuits and space station technology.

After several months of working on the suits, Axiom has revealed the details of the technology that will be worn by NASA astronauts returning to the moon on the Artemis III mission that's scheduled to land near the lunar south pole in 2025.

The newly revealed spacesuit will be worn by the first woman and first person of color to visit the moon. Photo courtesy of Axiom Space

“We’re carrying on NASA’s legacy by designing an advanced spacesuit that will allow astronauts to operate safely and effectively on the Moon,” says Suffredini in a statement from the company. “Axiom Space’s Artemis III spacesuit will be ready to meet the complex challenges of the lunar south pole and help grow our understanding of the Moon in order to enable a long-term presence there.”

Called the Axiom Extravehicular Mobility Unit, or AxEMU, the prototype was revealed at Space Center Houston’s Moon 2 Mars Festival today, March 15. According to Axiom, a full fleet of training spacesuits will be delivered to NASA by late this summer.

At the same time as the Ax-3 mission announcement, NASA also announced that it has selected Firefly Aerospace of Cedar Park, Texas, to carry multiple payloads to the far side of the Moon. According to NASA, the commercial lander will deliver two agency payloads, as well as communication and data relay satellite for lunar orbit, which is an European Space Agency collaboration with NASA.

The contract — awarded for around $112 million — is targeted to launch in 2026 through NASA’s Commercial Lunar Payload Services, or CLPS, initiative, and part of the agency’s Artemis program. It's the second award to Firefly under the CLPS initiative.

“The diversity of currently available commercial orbital human spaceflight opportunities is truly astounding. NASA’s commercial crew flights to the space station for our government astronauts paved the way for fully private missions to space like Inspiration4 and Polaris as well as private astronaut missions to the orbiting laboratory like the one we are announcing today,” says Phil McAlister, director of commercial space at NASA Headquarters in Washington, in the release. “We are starting to see the incorporation of space into our economic sphere, and it is going to revolutionize the way people see, use, and experience space.”

Axiom Space has announced its crew for its second commercial space launch. Image via Axiom

Houston space company announces historic flight crew

ready for liftoff

A Houston-based company is making history with its next commercial flight mission.

Axiom Space announced that Axiom Mission 2, or Ax-2, the second all-private mission to the International Space Station, will have members of the Kingdom of Saudi Arabia's national astronaut program aboard. It will also be the first private mission commanded by a woman: Peggy Whitson, Axiom's director of human spaceflight and former NASA astronaut.

“Axiom Space’s second private astronaut mission to the International Space Station cements our mission of expanding access to space worldwide and supporting the growth of the low-Earth orbit economy as we build Axiom Station,” says Michael Suffredini, president and CEO of Axiom Space, in a news release. “Ax-2 moves Axiom Space one step closer toward the realization of a commercial space station in low-Earth orbit and enables us to build on the legacy and achievements of the ISS, leveraging the benefits of microgravity to better life on Earth.”

Expected to launch this spring, it's the second ISS mission for the commercial aerospace company founded in 2016. Ax-2 Mission Specialists Ali Alqarni and Rayyanah Barnawi will be the first Saudi astronauts to visit the ISS after Axiom and the Kingdom of Saudi Arabia reached an agreement in 2022. With this mission, KSA will become only the sixth country to have two astronauts working on the ISS at the same time.

“This flight is an integral milestone of a comprehensive program aiming to train and qualify experienced Saudis to undertake human spaceflight, conduct scientific experiments, participate in international research, and future space-related missions contributing to the Kingdom’s Vision 2030,” reads a statement from the country.

Pilot John Shoffner, a businessman and aviator from Knoxville, Tennessee, with over 8,500 hours of flying under his belt, is the crew's fourth and final member.

A SpaceX Falcon 9 rocket will launch the Ax-2 crew aboard a SpaceX Dragon spacecraft to the ISS from NASA’s Kennedy Space Center in Florida, and they will spend 10 days on the mission. The mission is targeted for launch in the spring of 2023, and will be the first private space mission to include both private astronauts and astronauts representing foreign governments.

Whitson, a Rice university alum, will add to her deep resume, which also includes adding even more space time to the standing record for the longest cumulative time of any astronaut in the history of the U.S. space program.

“I am honored and excited to lead the Ax-2 crew and mission,” Whitson says in a statement. “The space station is a vital platform for all types of research. We at Axiom Space are committed to working with NASA to open the door for private citizens to contribute to and advance the groundbreaking research aboard the station, forging the path for us to operate, live and work abroad Axiom Station.”

Axiom aims to build its own commercial space station to launch in late 2025. Axiom’s first mission completed last April, and the company, deemed a unicorn with a $1 billion valuation, has raised $200 million, including a $130 million series B round in 2021.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

7+ can't-miss Houston business and innovation events in June 2026

where to be

Editor's note: The FIFA World Cup comes to Houston this month, joined by major energy conferences and a lineup of fan-favorite, recurring events. Here’s what not to miss and how to register. Please note: this article may be updated to add more events.


June 1-4 — CLEANPOWER 2026 Conference and Exhibition

CLEANPOWER unites policymakers, experts, and corporate leaders to solve the challenges that none can solve alone. This must-attend, four-day conference is packed with cutting-edge discussions about wind, solar, storage, and transmission; dealmaking; networking; and fun.

This event begins June 1 at the George R. Brown Convention Center. Register here.

June 2 — Humans of Healthcare

Houston Methodist Center for Innovation will present its quarterly speaker series, Humans of Healthcare. The series will feature a panel of experts who will share about their career paths and discuss the nuances of the health care industry. This month's session will focus on today’s nursing landscape, the industry’s expectations of nurses and what career paths are possible in the field.

The event is Tuesday, June 2, from 5-6:30 p.m. at the Ion. Register here.

June 9 — Greentown Go Make Kickoff

Head to the Ion to celebrate the Greentown Go Make 2026 cohort. The open-innovation program with Shell Catalysts & Technologies and Technip Energies focuses on catalytic solutions for industrial decarbonization and the energy transition. Hear pitches from the founders and network with a select group of startups while enjoying food and drink.

This event is Tuesday, June 9, from 5:30-8 p.m. Register here.

June 9-10 — Texas Brain Economy Summit

The Center for Houston’s Future and UTMB are bringing the Texas Brain Economy Summit back to Houston this summer to continue to position the region as a global leader in brain health. Expect to hear from leaders of global institutions, including the World Economic Forum, U.S. Chamber of Commerce, McKinsey Health Institute, Global Brain Economy Initiative, Davos Alzheimer’s Collaborative, Business Collaborative for Brain Health (UsAgainstAlzheimer’s), Rice University, Memorial Hermann, MD Anderson and many others. Read InnovationMap's full preview of the event here.

This event begins Tuesday, June 9. Purchase tickets here.

June 10 — MIT Future of Healthcare Technology Forum

The MIT Club of South Texas will host an in-person forum to explore how innovation, government and policy are changing the healthcare industry. The event will feature MIT alumni and Houston healthcare leaders, including Dr. Tim Boone, dean of the Texas A&M School of Engineering Medicine; Cynthia Reinhart-King, chair of bioengineering at Rice University; Dr. Tony Lin, CEO and chairman emeritus of Kelsey-Seybold Clinic; and others.

This event is Wednesday, June 10, from 5:15-8:30 p.m. at the TAMU EnMed Building. Register here.

June 11 — Goals & Gigawatts: Houston Energy & Climate Week The Power of & Kickoff Party

Come watch the Mexico City FIFA opening match while celebrating energy and innovation at the Goals & Gigawatts Kickoff Party. The event will feature food, drinks, and a showcase on Houston Energy & Climate Week. Learn what to expect and how to get involved in HECW before closing the night with a DJ and karaoke.

This event is Thursday, June 11, from 1:30-6:30 p.m. Find more information here.

June 16-17 — Energy Projects Conference & Expo

The Energy Projects Conference & Expo (EPC Show) is the largest event in North America for professionals working at the heart of major energy projects. The essential event for engineering, construction, commissioning, operations and maintenance across multiple energy sectors brings together five leading conferences under one roof. Conference subjects span LNG exporting, hydrogen and ammonia, midstream, petrochem and refining, and sustainable aviation fuels.

This event begins June 16 at George R. Brown Convention Center. Register here.

June 25 – NASA Tech Talk

Every fourth Thursday of the month, NASA experts, including longtime engineer Montgomery Goforth, present on technology development challenges NASA’s Johnson Space Center and the larger aerospace community are facing, and how they can be leveraged by Houston’s innovation community. Stick around after for drinks and networking at Second Draught.

This event is Thursday, June 25, from 6-7 p.m. at the Ion. Register here.

Houston researchers report promising first in-human trial for implantable cancer therapy

cancer breakthrough

When it comes to cancer remedies, the treatment can be as challenging for the body as its cause. But what if immunotherapy could be localized? That’s precisely what a Houston team may soon make a reality.

Rice University researchers, in partnership with MD Anderson Cancer Center, recently published their findings from the first in-human trial of an implantable cancer-fighting treatment in the journal Clinical Cancer Research. The paper details testing of AVB-001, encapsulated cells engineered to release interleukin-2 (IL-2)—a naturally occurring signaling protein that boosts immunity—in the peritoneal cavities of 14 patients. The goal is to avoid the toxicity usually experienced with less targeted treatments, as well as find a solution to IL-2s’ abbreviated half-lives.

“Traditional IL-2 therapy has shown potent antitumor activity, but its clinical use has been limited by severe side effects and delivery challenges,” Omid Veiseh, director of the Rice Biotech Launch Pad, professor of bioengineering at Rice and a senior author on the study, said in a press release. “This platform allows us to localize and sustain cytokine exposure directly where tumors reside while minimizing systemic toxicity.”

Serous ovarian carcinoma is especially well-suited to the use of AVB-001 because it tends to spread throughout the abdomen. After a minimally invasive laparoscopic procedure, patients implanted with the cells were noted to tolerate the treatment well. Half of the enrolled patients’ cancer was stabilized, with several among them reporting extended signs of benefit. No maximum tolerated dose was reached and there were no life-threatening events tied to the study.

If that sounds like less-than-earth-shaking results, this is only the beginning. The capsules were implanted for about one week because IL-2 activity drops off after that. The researchers now know that further testing should include either higher levels, repeated doses, or a combination thereof, in order to create stronger advances.

The team has already made early headway on this next step. Preclinical studies in nonhuman primates were not only tolerated well, but without added toxicity, the apes had consistent pharmacological effects.

“This is a foundational step,” Veiseh explained. “We now have evidence that the platform is safe, biologically active and potentially scalable. The next phase is optimizing dosing and exploring combination therapies to unlock its full clinical potential.”

The combination would also include a checkpoint inhibitor, which might improve AVB-001’s tumor-fighting power. “What is exciting is that we are not just delivering a drug, we are programming a microenvironment,” added Dr. Amir Jazaeri, professor of gynecologic oncology at MD Anderson, member of the Rice Biotech Launch Pad’s clinical advisory board and a senior author on the study. “This opens the door to combination strategies that could amplify immune responses in ways that have not been feasible before.”